Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 6/2012

01-12-2012 | Original Paper

[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies

Authors: Juha O. Rinne, Dean F. Wong, David A. Wolk, Ville Leinonen, Steven E. Arnold, Chris Buckley, Adrian Smith, Richard McLain, Paul F. Sherwin, Gill Farrar, Marita Kailajärvi, Igor D. Grachev

Published in: Acta Neuropathologica | Issue 6/2012

Login to get access

Abstract

Molecular imaging techniques developed to ‘visualize’ amyloid in vivo represent a major achievement in Alzheimer’s disease (AD) research. This pooled analysis of four studies determined the level of association between uptake of the fibrillar amyloid β positron emission tomography (PET) imaging agent [18F]flutemetamol (Pittsburgh Compound B analog with a 5.5 times longer half-life to enable it to be used in the clinical setting) and neuritic plaques and fibrillar amyloid β measured by pathologic staining of cortical region biopsy samples. Fifty-two patients with suspected normal pressure hydrocephalus underwent prospective (n = 30) or retrospective (n = 22) [18F]flutemetamol PET imaging for detection of cerebral cortical fibrillar amyloid β and cortical brain biopsy during intracranial pressure measurement or ventriculo-peritoneal shunting. [18F]Flutemetamol uptake was quantified using standardized uptake value ratio (SUVR) with cerebellar cortex as the reference region. Tissue fibrillar amyloid β was evaluated using immunohistochemical monoclonal antibody 4G8 and histochemical agents Thioflavin S and Bielschowsky silver stain, and an overall pathology result based on all available immunohistochemical and histochemical results. Biopsy site and contralateral [18F]flutemetamol SUVRs were significantly associated with neuritic plaque burden assessed with Bielschowsky silver stain (r spearman’s = 0.61, p = 0.0001 for both), as was the composite SUVR with biopsy pathology (r spearman’s = 0.74, p < 0.0001). SUVR and immunohistochemical results with 4G8 for detecting fibrillar amyloid β were similar. Blinded image evaluation showed strong agreement between readers (κ = 0.86). Overall sensitivity and specificity by majority read were 93 and 100 %. Noninvasive in vivo [18F]flutemetamol PET imaging demonstrates strong concordance with histopathology for brain fibrillar amyloid β, supporting its promise as a tool to assist physicians with earlier detection of the disease process and making diagnostic decisions about concomitant AD and other diseases associated with brain amyloidosis.
Appendix
Available only for authorised users
Literature
1.
Bacskai BJ, Frosch MP, Freeman SH et al (2007) Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 64:431–434PubMedCrossRef
2.
Bancroft JD, Gamble M (eds) (2007) Theory and practice of histological techniques, 6th edn. Churchill Livingstone, Elselvier
3.
Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357PubMedCrossRef
4.
Buckley C, Ikonomovic M, Smith A, Heurling K, Farrar G, Brooks D, Grachev I, McLain R, Sherwin P et al (2012) Flutemetamol F 18 injection PET images reflect brain beta-amyloid levels. Alzheimer’s Dementia: J Alzheimer’s Assoc 8(Suppl):P90CrossRef
5.
Cooper JH (1969) An evaluation of current methods for the diagnostic histochemistry of amyloid. J Clin Pathol 22:410–413PubMedCrossRef
6.
Cotran RS, Kumar V, Robbins SL (1989) Alzheimer’s Disease. In: Kumar V, Abbas AK, Aster J, Fausto N (eds) Robbins pathologic basis of disease. WB Saunders, Philadelphia, pp 1427–1429
7.
Edison P, Archer HA, Hinz R et al (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68:501–508PubMedCrossRef
8.
Edison P, Hinz R, Brooks DJ. Technical aspects of amyloid imaging for Alzheimer’s disease (2011) Alzheimers Res Ther 3:25
9.
Engler H, Forsberg A, Almkvist O et al (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 129(Pt 11):2856–2866PubMedCrossRef
10.
Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465PubMedCrossRef
11.
Golomb J, Wisoff J, Miller DC et al (2000) Alzheimer’s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry 68:778–781PubMedCrossRef
12.
Hamilton R, Patel S, Lee EB et al (2010) Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol 68:535–540PubMedCrossRef
13.
Harrison RS, Sharpe PC, Singh Y, Fairlie DP (2007) Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 159:1–77PubMedCrossRef
14.
Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56:1095–1097PubMedCrossRef
15.
Ikonomovic M, Price J, Abrahamson E, Mathis C, Paljug W, Debnath M, Shao L, Becker C, Hamilton R, Klunk W (2012) Direct correlations of [H-3]flutemetamol binding with [H-3]PiB binding and amyloid-beta concentration and plaque load in [C-11]PiB imaged brains (S34.002). Neurology 78:S34.002
16.
Ikonomovic MD, Klunk WE, Abrahamson EE et al (2008) Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131:1630–1645PubMedCrossRef
17.
Jack CR Jr, Lowe VJ, Senjem ML et al (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain 131(pt 3):665–680PubMedCrossRef
18.
Jack CR Jr, Lowe VJ, Weigand SD et al (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132:355–365CrossRef
19.
Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128PubMedCrossRef
20.
Klunk WE (2008) Biopsy support for the validity of Pittsburgh Compound B positron emission tomography with a twist. Arch Neurol 65:1281–1283PubMedCrossRef
21.
Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319PubMedCrossRef
22.
Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 129(Pt 11):2805–2807PubMedCrossRef
23.
Koivunen J, Pirttila T, Kemppainen N et al (2008) PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 26:378–383PubMedCrossRef
24.
Koivunen J, Scheinin N, Virta JR et al (2011) Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 76:1085–1090PubMedCrossRef
25.
Leinonen V, Alafuzoff I, Aalto S et al (2008) Assessment of β-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography by carbon-11 labelled Pittsburgh Compound B. Arch Neurol 65:1304–1309PubMedCrossRef
26.
Leinonen V, Koivisto AM, Savolainen S et al (2010) Amyloid and tau proteins in cortical brain biopsy and Alzheimer’s disease. Ann Neurol 68:446–453PubMedCrossRef
27.
Leinonen V, Koivisto AM, Savolainen S et al (2012) Post-mortem findings in 10 patients with presumed normal pressure hydrocephalus and review of the literature. Neuropathol Appl Neurobiol 38:72–86PubMedCrossRef
28.
Lin KJ, Hsu WC, Hsiao IT et al (2010) Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent—a pilot study. Nucl Med Biol 37:497–508PubMedCrossRef
29.
Lopresti B, Klunk WE, Mathis CA et al (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959–1972PubMed
30.
Mirra SS, Heyman A, McKeel D (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedCrossRef
31.
Montine TJ, Phelps CH, Beach TG et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11PubMedCrossRef
32.
Nelissen N, Van Laere K, Thurfjell L et al (2009) Phase 1 study of the Pittsburgh Compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer’s disease. J Nucl Med 50:1251–1259PubMedCrossRef
33.
Raji CA, Becker JT, Tsopelas ND et al (2008) Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer’s disease with Pittsburgh Compound B. J Neurosci Methods 172:277–282PubMedCrossRef
34.
Rinne JO, Brooks DJ, Rossor MN et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372PubMedCrossRef
35.
Rossetti HC, Munro CC, Hynan LS, Lacritz LH (2010) The CERAD neuropsychologic battery total score and the progression of Alzheimer disease. Alzheimer Dis Assoc Disord 24:138–142PubMedCrossRef
36.
Rowe CC, Ackerman U, Browne W et al (2008) Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129–135PubMedCrossRef
37.
Rowe CC, Ellis KA, Rimajova M et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275–1283PubMedCrossRef
38.
Rowe CC, Ng S, Ackermann U et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718–1725PubMedCrossRef
39.
Seppälä TT, Nerg O, Koivisto AM et al (2012) CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 78:1568–1575PubMedCrossRef
40.
Small GW, Kepe V, Ercoli LM et al (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663PubMedCrossRef
41.
Spillantini MG, Goedert M, Jakes R, Klug A (1990) Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci USA 87:3947–3951PubMedCrossRef
42.
Storandt M, Mintun MA, Head D, Morris JC (2009) Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh Compound B: cognitive decline associated with Abeta deposition. Arch Neurol 66:1476–1481PubMedCrossRef
43.
Thal DR, Rub U, Orantes M et al (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800PubMedCrossRef
44.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15:273–289PubMedCrossRef
45.
Vallet PG, Guntern R, Hof PR et al (1992) A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer’s disease. Acta Neuropathol 83:170–178PubMedCrossRef
46.
Vandenberghe R, Van Laere K, Ivanoiu A et al (2010) 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 68:319–329PubMedCrossRef
47.
Verhoeff NP, Wilson AA, Takeshita S et al (2004) In vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12:584–595PubMed
48.
Wolk DA, Grachev ID, Buckley C et al (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68:1398–1403PubMedCrossRef
49.
Wolk DA, Klunk W (2009) Update on amyloid imaging: from healthy aging to Alzheimer’s disease. Curr Neurol Neurosci Rep 9:345–352PubMedCrossRef
50.
Wolk DA, Price JC, Saxton JA et al (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557–568PubMedCrossRef
51.
Wolk D, Rinne J, Wong D, Leinonen V, Arnold S, Buckley C, Smith A, McLain R, Sherwin P, Farrar G, Kailajarvi M, Grachev I (2012) [18F]-Flutemetamol PET amyloid imaging and cortical biopsy histopathology in normal pressure hydrocephalus: pooled analysis of four studies (S34.001) Neurology 78:S34.001
52.
Wong DF, Moghekar AR, Rigamonti D, Brašić JR, Rousset O, Willis W, Buckley C, Smith A, Gok B, Sherwin P, Grachev ID (2012) An in vivo evaluation of cerebral cortical amyloid with [(18)F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mole Imaging Biol Aug 10 [epub ahead of print]
53.
Wu C, Pike VW, Wang Y (2005) Amyloid imaging: from benchtop to bedside. Curr Top Dev Biol 70:171–213PubMedCrossRef
Metadata
Title
[18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies
Authors
Juha O. Rinne
Dean F. Wong
David A. Wolk
Ville Leinonen
Steven E. Arnold
Chris Buckley
Adrian Smith
Richard McLain
Paul F. Sherwin
Gill Farrar
Marita Kailajärvi
Igor D. Grachev
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 6/2012
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-012-1051-z

Other articles of this Issue 6/2012

Acta Neuropathologica 6/2012 Go to the issue

Original Paper

LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR)

Original Paper

Amyloid plaque formation precedes dendritic spine loss

Editorial

The next step in brain tumor classification: “Let us now praise famous men”… or molecules?

Original Paper

Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques

Correspondence

Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma

Review

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited